nivolumab
bms
['nivo', 'nivolumab']
 2022: upfront nephrectomy do not benefit to all patients according to meet-uro 15 study (nivolumab in pre-treated patients): still an argument to select patients after immunotherapy to discuss delayed nephrectomy for good responders. 
urologue à L'institut Paoli-Calmettes à Marseille